Biotie Therapies to present at Rodman & Renshaw Annual Healthcare
Conference

(Thomson Reuters ONE) - BIOTIE THERAPIES CORP. Press Release September 4, 2009 at 11a.m.Biotie Therapies to present at Rodman & Renshaw Annual HealthcareConferenceRodman & Rodman Annual Global Investment Conference 2009Live webcast will be available at www.biotie.comBiotie Therapies Corp. (NASDAQ OMX: BTH1V) announced today that Dr.Timo Veromaa, President and Chief Executive Officer, will give anupdate on the company at the Rodman & Renshaw 11th Annual HealthcareConference in New York on Wednesday September 9, 2009 at 10:50 a.m.local time (5:50 p.m. Finnish time).For more information on the conference:http://www.rodmanrenshaw.com/conferences?id=30The audio and slide presentation will be webcasted live and will beavailable for 90 days at www.biotie.com.For further information, please contact:Virve Nurmi, Biotie Therapies Corp.tel. +358 2 274 8900, e-mail: virve.nurmi(at)biotie.comAbout Biotie Therapies Corp.Biotie is a drug discovery and development company focused on centralnervous system and inflammatory diseases. It has a broad range ofinnovative small molecule and biological drug candidates at differentstages of clinical and pre-clinical development. Biotie's productsaddress diseases with high unmet medical need and significant marketpotential, including addiction and psychotic disorders, rheumatoidarthritis, psoriasis and chronic obstructive pulmonary disease(COPD). The most advanced product, nalmefene for alcohol dependence,is currently in phase III clinical development by licensing partnerH. Lundbeck A/S.The commercial value of the pipeline has been demonstrated throughexisting alliances with top-tier global pharmaceutical companies suchas Lundbeck, Roche and Wyeth. Biotie has operations in Turku, Finlandand Radebeul, Germany.Shares are listed on NASDAQ OMX Helsinki Ltd.For more information, please refer to www.biotie.comThis announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.

Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
Datum: 04.09.2009 - 10:00 Uhr
Sprache: Deutsch
News-ID 5497
Anzahl Zeichen: 0

contact information:
Town:

London

Kategorie:

Business News

Diese Pressemitteilung wurde bisher 322 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Biotie Therapies to present at Rodman & Renshaw Annual Healthcare
Conference"
steht unter der journalistisch-redaktionellen Verantwortung von

Biotie Therapies Oyj (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Biotie Announces Start of Clinical Study With Nepicastat (SYN117) in Cocaine Dep ...

TURKU, FINLAND -- (Marketwired) -- 05/10/13 -- BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 10 May 2013 at 9.00 a.m.Biotie Therapies today announced the start of a Phase 2 clinical study evaluating nepicastat (SYN117) in cocaine dependence. The Nat ...

Biotie: Selincro Launched in the United Kingdom ...

TURKU, FINLAND -- (Marketwired) -- 05/06/13 -- Biotie today announced that its partner H.Lundbeck A/S (Lundbeck) has launched Selincro in the United Kingdom. According to the terms of the license agreement between Biotie and Lundbeck for Selincro, B ...

Biotie: Selincro Launched in First European Markets ...

TURKU, FINLAND -- (Marketwired) -- 04/22/13 -- BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 22 April 2013 at 9:00 a.m.Biotie today announced that its partner H.Lundbeck A/S (Lundbeck) has started launching Selincro™ in the first European markets, ...

Alle Meldungen von Biotie Therapies Oyj